Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

InMed Pharmaceuticals Inc. (INM) had Revenue of $4.94M for the most recently reported fiscal year, ending 2025-06-30.

Quarterly Annual

Figures for fiscal year ending 2025-06-30

Income Statement Financials
Revenue	$4.94M
Net Income	$-8.16M
Cost of Goods Sold	$3.24M
Gross Profit	$1.71M
Operating Expenses	$12.86M
Operating Income	$-7.92M
Non-Operating Income/Expense	$-0.24M
Pre-Tax Income	$-8.16M
Normalized Pre-Tax Income	$-8.16M
Income after Taxes	$-8.16M
Income from Continuous Operations	$-8.16M
Consolidated Net Income/Loss	$-8.16M
Normalized Income after Taxes	$-8.16M
EBIT	$-7.92M
EBITDA	$-7.71M
Weighted-Average Shares Outstanding (Basic)	0.98M
Weighted-Average Shares Outstanding (Diluted)	0.98M
Earnings per Share (EPS) (Basic)	$-8.36
Earnings per Share (EPS) (Diluted)	$-8.36
Balance Sheet Financials
Current Assets	$12.87M
Property, Plant, and Equipment	$0.99M
Long-Term Assets	$2.71M
Total Assets	$15.58M
Current Liabilities	$1.84M
Long-Term Debt	$0.31M
Long-Term Liabilities	$0.31M
Total Liabilities	$2.15M
Common Equity	$13.43M
Tangible Shareholders Equity	$11.81M
Shareholders Equity	$13.43M
Common Shares Outstanding	2.00M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-7.77M
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	$12.27M
Beginning Cash	$6.57M
End Cash	$11.08M
Increase/Decrease in Cash	$4.50M
Stock-Based Compensation	$0.12M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	6.99
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.02
Debt to Equity Ratio	0.06
Gross Margin	34.53%
Operating Margin	-160.20%
EBIT Margin	-160.20%
EBITDA Margin	-155.89%
Pre-Tax Profit Margin	-165.14%
Profit Margin	-165.14%
Free Cash Flow	$-7.77M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.32
Inventory Turnover	3.37
Receiveable Turnover	10.63
Days Sales in Receivables	34.35
Return on Equity	-60.76%
Return on Tangible Equity	-69.09%
Return on Assets	-52.39%
Return on Investments	-59.40%
Book Value Per Share	$6.71
Free Cash Flow per Share	$-7.96
Operating Cash Flow per Share	$-7.96

Data from Zacks Investment Research, Inc.